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Summary Navelbine (NVB, vinorelbine ditartrate, KW-2307), a new vinca alkaloid analogue, has been shown to be clinically effective against
advanced breast cancer. In this report, the combined effect of NVB with medroxyprogesterone acetate (MPA), a synthetic progesterone
derivative, was examined in vitro against human breast carcinoma MCF-7 cells. The combined effect was demonstrated to be synergistic
using the isobologram and median-effect plot analyses. To elucidate the mechanism of action, we further examined effects of both drugs on
cell cycle distribution of the cells in combination and/or alone. NVB at 2 nm induced apparent G1-phase accumulation as well as the induction
of cyclin-dependent kinase (CDK) inhibitor p21WAF1/cIPl protein and the dephosphorylated form of retinoblastoma protein (pRb). In contrast,
MPA at 0.1 gM also induced G1-phase accumulation as well as the reduced expression of cyclin Dl protein. In addition, the combination of
both drugs induced augmented G1-phase accumulation, which occurred along with p21WAF1/cIPl protein induction, cyclin Dl protein reduction
and pRb dephosphorylation. These results demonstrate that the synergistic combined effect of NVB with MPA was mediated through
enhancement of G1-phase accumulation that resulted from the different action point(s) of each drug. Furthermore, the synergistic combined
effect of NVB with MPA was also observed in other human breast carcinoma cell lines, such as T-47D and ZR-75-1. These results suggest
that combination therapy of NVB with MPA in breast cancer might be effective in clinical studies.
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Navelbine (NVB, vinorelbine ditartrate, KW-2307) is a new vinca
alkaloid analogue that has been shown to be clinically active
against advanced and/or metastatic breast cancer as a single agent
(Bruno et al, 1995; Gasco et al, 1997; Livingston et al, 1997). The
drug has been also shown to exert objective clinical outcome in
combination with other chemotherapeutic agents, such as doxo-
rubicin, mitomycin C and ifosfamide as a first-line or second-line
therapy for advanced breast cancer (Agostara et al, 1994;
Spielmann et al, 1994; Hochster, 1995; Pronzato et al, 1997).
Medroxyprogesterone acetate (MPA) is a synthetic proges-
terone derivative that has been shown to be clinically effective
against advanced breast cancer as a second-line hormonal therapy
after tamoxifen (Pannuti et al, 1979; Becher et al, 1989). MPA has
also been shown to augment the efflcacy ofcombined chemother-
apeutic modality for breast cancer [such as cyclophosphamide
doxorubicin and 5-fluorouracil (CAF)] and to ameliorate side-
effects caused by chemotherapeutic agents (Hupperets et al, 1993;
Tominaga et al, 1994), thus establishing chemohormonal therapy.
Based on these findings, we have asked whether the combina-
tion of NVB with MPA, as a chemohormonal therapy, would be
valuable, using cultured human breast carcinoma MCF-7 cells in
vitro. Isobologram analysis as well as median-effect plot analysis
revealed that the combined effect of NVB with MPA was appar-
ently synergistic. As NVB is known to inhibit the assembly of
microtubles, thus inducing mitotic arrest in the cells (Gomi et al,
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1992), and MPA is shown to induce GI-phase accumulation
(Sutherland et al, 1988), we examined the effect of the combina-
tion of both drugs on cell cycle distribution of MCF-7 cells.
Unexpectedly, NVB showed GI-phase accumulation both alone
and in combination with MPA. Under these circumstances, to
examine the mechanism of action of G1-phase accumulation, we
have also asked whether NVB and/or MPA affects the expression




Navelbine (NVB, vinorelbine ditartrate, KW-2307) and medroxy-
progesterone acetate (MPA) were obtained from Kyowa Hakko
Kogyo, Tokyo, Japan. NVB was dissolved in dimethyl sulphoxide
(Wako Pure Chemical Industries, Osaka, Japan). MPA was
dissolved in ethanol (Kanto Chemical, Tokyo, Japan). Tris hydroxy
aminomethane and Tween 20 were purchased from Bio-Rad
Laboratories, Hercules, CA, USA. Sodium chloride, sodium fluo-
ride and ethylenediamine tetra acetic acid (EDTA) were purchased
from Kanto Chemical. Triton X-100 was purchased from
Yoneyama Yakuhin Kogyo, Osaka, Japan. N-2-hydroxyethylpiper-
azine-N'-2-ethanesulphonic acid (HEPES), P-glycerophosphate,
sodium o-vanadate, phenylmethylsulphonyl fluoride, aprotinin and
leupeptin were purchased from Sigma Chemical, St Louis, MO,
USA. Anti-pRb and anti-p21wAFl/cIPl monoclonal antibodies were
purchased fromPharMingen, San Diego, CA, USA. Anti-cyclin Dl
monoclonal antibody was purchased from IBL, Gunma, Japan, and
anti-cyclin E monoclonal antibody was purchased from Santa Cruz
17371738 KSugiyama etal
Biotechnology, Santa Cruz, CA, USA. Anti-cyclin A and anti-
CDK2 monoclonal antibodies were prepared as described previ-
ously (Akiyama et al, 1997).
Cell culture
MCF-7 (Soule et al, 1973), T-47D (Keydar et al, 1979), BT-474
(Lasfargues et al, 1978) and MDA-MB-453 (Cailleau et al, 1978)
cells were purchased from the American Type Culture Collection,
Rockville, MD, USA. ZR-75-1 cells (Engel et al, 1978) were
purchased from the American Type Culture Collection through
Dainippon Pharmaceutical, Osaka, Japan. MCF-7, T-47D and ZR-
75-1 cells were passaged in RPMI-1640 medium (Gibco, Grand
Island, NY, USA) containing 10% fetal bovine serum (Filtron,
Brooklyn, Australia), 100 IU penicillin, 100 ,ug ml-1 streptomycin
(Gibco) and 10 nM 17p-estradiol (Sigma) at 37°C in a humidified
atmosphere containing 5% carbon dioxide in air. BT-474 cells was
passaged in the above medium containing 10 jg ml-1 insulin
(Sigma) at 37°C in ahumidified atmosphere containing 5% carbon
dioxide in air. MDA-MB-453 cells werepassaged in L-15 medium
(Sigma) containing 10% fetal bovine serum, 100 IU penicillin and
100 jig ml-' streptomycin at 37°C in a humidified atmosphere.
Growth-inhibitory activity
MCF-7 cells (5 x 103 per 0.5 ml per well) were precultured in the
culture medium for 24 h in 24-well multidishes (Nunc, Roskilde,
Denmark). Then the cells were treated with the drug(s) for the
period indicated in the text. The drug treatment was terminated by
washing the cells with phosphate-buffered saline without calcium
[PBS(-)] (ICN Biomedicals, Aurora, OH, USA), and the cells
were placed in drug-free medium. The cell number was counted
using a micro-cell counter (F-300; Toa Medical Electronics,
Hyogo, Japan) after the treatment of the cells with 0.05% trypsin











Figure 1 Exposure time dependency of the growth-inhibitory activity of NVB
(-) and MPA (0). MCF-7 cells (5 x 103 per well) were cultured on day 0 and
treated with each drug from day 1 for the indicated exposure time. Cell
number was counted on day 7
Analysis of the combined effect using the isobologram
method
Cells were precultured in the culture medium for 24 h in 96-well
microwell plates (Nunc). Then, the cells were exposed to drugs
according to the following schedules: simultaneous exposure to
both drugs for 144 h, sequential exposure to NVB for 24 h
followed by MPA for 120 h and sequential exposure to MPA for
120 h followed by NVB for 24 h. Cell viability was determined by
MTT assay (Mosmann, 1983). The combination effect of NVB
with MPA was assessed by means of isobologram analysis
(Berenbaum, 1981).
Analysis of the combined effect using the
median-effect plot method
MCF-7 cells (2.5 x 103 per 0.25 ml per well) were precultured in
the culture medium for 24 h in 24-well multidishes. The cells were
exposed to both drugs for 144 h. The growth-inhibitory activity
was evaluated by counting cell number using a micro-cell counter
afterseparating the cells by treatment with trypsin-EDTA solution.
The combined effect of both drugs was determined by median-
effect plot analysis (Chou and Talalay, 1984).
Cell cycle analysis
MCF-7 cells (1.5 x 105 per 10 ml per dish) were precultured in the
culture medium for 24 h in a 100-mm culture dish (Falcon 3003;
Becton Dickinson, Lincoln Park, NJ, USA). The cells were incu-
bated with the drugs for the indicated time and were harvested by
trypsin-EDTA treatment. The cells were then fixed with ice-cold
70% ethanol solution and stored at 4°C. After the cells were
washed with PBS(-), they were incubated with PBS(-) containing
250 jg ml-' ofribonuclease A (type 1-A, Sigma), 0.1% Nonidet P-
40 (Nacalai Tesque, Kyoto, Japan) for 30 min at 37°C. The cells
were stained with propidium iodide (Sigma) at a final concentra-
tion of 50 jg ml-1 for 20 min on ice. Fluorescence of individual
cells was measured with a flow cytometer (Epics Elite, Coulter,
Hialeah, FL, USA). The cell cycle distribution was calculated
using a Multicycle program (Coulter).
Western blotting
Exponentially growing MCF-7 cells, exposed to NVB and/or MPA
for 24 h, were harvested by treatment with trypsin-EDTA solution,
washed with PBS(-) and stored at -80°C. The cells were lysed in
lysis buffer [50 mM HEPES/sodium hydroxide (pH 7.4), 150mM
sodium chloride, 0.1% Triton X-100, 50 mm sodium fluoride,
80 mm [B-glycerophosphate, 0.1 mm sodium o-vanadate, 1 mM
EDTA, 1 mm phenylmethylsulphonyl fluoride, 1 jg ml-' aprotinin,
1 jg ml-' leupeptin] (Rosenblatt et al, 1992) for 20 min at 4°C. The
cell lysates were clarified by centrifugation at 14000 r.p.m. for
10 min at 4'C and the protein contents were determined using the
protein assay kit (Bio-Rad Laboratories). Equal amounts ofprotein
were heated in sodium dodecyl sulphate (SDS) sample buffer
(Laemmli, 1970) for 5 min at 95°C, subjected to SDS-polyacry-
lamide gel electrophoresis and transferred onto p-membranes
(AlTO, Tokyo, Japan). The membranes were incubated in blocking
buffer [5% skim milk (Yukijirushi Nyugyo, Hokkaido, Japan) in
Tris-buffered saline], probed with primary antibodies followed by
secondary antibody conjugated with horseradish peroxidase
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Figure 2 The combined effect of NVB with MPA was analysed by the
classical isobologram analysis using the IC50 (A-C) and IC70 (D-F) values for
MCF-7 cells. (A and D) Simultaneous exposure to both drugs for 144 h.
(B and E) Sequential exposure to NVB for 24 h followed by MPA for 120 h.
(C and F) Sequential exposure to MPA for 120 h followed by NVB for 24 h
(Amersham Life Sciences, Buckinghamshire, UK) and detected
using an enhanced chemiluminescence system (Amersham).
RESULTS
Kinetic analysis of cell growth-inhibitory activity of
NVB and MPA
We carried out kinetic analysis of the cell growth-inhibitory
activity of NVB and MPA to determine whether the growth-
inhibitory activity of both drugs was AUC dependent or time
dependent (Gomi et al, 1992). As shown in Figure 1, NVB showed
time-dependent growth-inhibitory characteristics in MCF-7 cells
as previously reported. MPA showed plots with a gentle slope, the
pattern of which demonstrated neither AUC nor time dependency
(Figure 1). From these results we decided to use exposure time as
follows to obtain full activity: 24 h for NVB and 144 h for MPA.
Analysis of the combined effect of NVB with MPA for
MCF-7 cells
To determine the combined effect of NVB with MPA, classical
isobologram analysis was performed using the IC50 (cytostatic
condition) and IC70 (cytotoxic condition) values for MCF-7 cells.
Isobologram analysis on various treatment schedules, such as
simultaneous exposure to both drugs (Figure 2A and D), sequen-
tial exposure to NVB followed by MPA (Figure 2B and E) and
sequential exposure to MPA followed by NVB (Figure 2C and F)
Figure 3 The combined effect of NVB with MPA was analysed using the
median-effect plot analysis for MCF-7 cells. (A) The cells (2.5 x 103 per well)
were cultured on day 0 and treated with NVB (0), MPA (0) or NVB plus MPA
(-) on day 1. For the combination, 1.5-fold dilutions of the two drugs were
prepared (0.53-6.08 nM NVB and 10.7-122 nm MPA), and they were
combined with each other from the lowest concentration. Drug
concentrations were expressed based on NVB concentration. The cell
number was counted on day 7. (B) Median-effect plot calculated using the
results of A
revealed that the combination effect of NVB and MPA was
synergistic in all the treatment schedules tested. In addition, a
synergistic combined effect was observed in both cytostatic and
cytotoxic conditions (Figure 2A-C, compared with Figure 2D-F).
The combined effect ofNVB with MPA was also assessed using
median-effect plot analysis. For the analysis, 1.5-fold dilutions of
the two drugs were prepared (0.53-6.08 nM NVB and 10.7-
122 nM MPA), and they were combined with each other from the
lowest concentration (Figure 3). The combination index (CI)
values ofthe group treated with NVB and MPA were less than 1 at
the wide range of concentrations (Figure 3B), indicating that the
growth-inhibitory activity in the combination regimen was syner-
gistic (Chou and Talalay, 1984), consistent with the results of the
isobologram analysis.
Growth curve of MCF-7 cells treated with both drugs
To set up the condition for cell cycle analysis, the growth pattern
of MCF-7 cells was examined by simultaneous treatment of the
cells with NVB and MPA for 144 h. Combination of 0.5 nm NVB
with 0.1 gM MPA showed no combined effect (Figure 4A),
however the combination of 1 nm or 2 nm NVB with 0.1 ,UM MPA
exhibited synergistic growth inhibition (Figure 4B and C). When
4 nm NVB was combined with 0.1 ,UM MPA, the growth-inhibitory
effect was similar to that of NVB alone (Figure 4D), which is
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Figure 4 Growth curve of MCF-7 cells treated with NVB plus MPA. The
cells (5 x 103 per well) were cultured on day 0, and treated with MPA 0.1 gM,
NVB [(A) 0.5 nM, (B) 1 nm, (C) 2 nm and (D) 4 nM] or NVB plus MPA from day
1 for 144 h. 0, untreated; 0, MPA alone; A, NVB alone; *, NVB plus MPA
consistent with the results obtained from the median-effect plot
analysis.
Cell cycle analysis
From the results shown in Figure 4, we fixed the concentration of
NVB as 2 nm and that of MPA as 0.1I,M for cell cycle analysis.
DNA histograms of MCF-7 cells treated with NVB alone, MPA
alone or NVB plus MPA are shown in Figure 5. Treatment of
MCF-7 cells with 2 nm of NVB alone showed apparent GI-phase
accumulation with decrease ofcells in S-phase 24 h after the treat-
ment, and the effects persisted until 72 h after drug treatment. The
G,-phase accumulation was also observed in the cells treated with
4 nM of NVB alone (Figure SB). The cells treated with 0.1 JIM of
MPA alone accumulated in GI-phase 24 h after treatment, and the
effects persisted until 72 h; 1 ,UM of MPA alone also showed G -
phase accumulation in the cells (Figure SC). In addition, combina-
tion of NVB with MPA showed more profound GI-phase
accumulation than each drug alone at each time point (Figure SA).
These results suggest that the synergistic combined effect ofNVB
with MPA might be caused through the augmentation ofGI-phase
accumulation ofeach drug alone.
Combined effect of NVB with MPA on the
phosphorylation state of pRb and CDK2 protein and
protein expression of CDK inhibitor p2lWAFl/CIP1
Results from the cell cycle analysis suggested thatG,-phase accu-
mulation might play an important role in the combined effect of
NVB with MPA. In order to elucidate the mechanism of action of
NVB and/or MPA-induced GI-phase accumulation in MCF-7
cells, we have analysed the phosphorylation state of pRb, which
plays an important role in G, to S-phase transition in mammalian
cells (Weinberg, 1995). As shown in Figure 6A, in untreated expo-
nentially growing MCF-7 cells, pRb was constitutively hyper-
phosphorylated and migrated slower than the underphosphorylated
form in SDS-polyacrylamide gel (Weinberg, 1995). After a 24 h
exposure ofthe cells to 2 nM ofNVB, the accumulation ofdephos-
phorylated, faster migrating pRb was observed (Figure 6A). In
contrast, MPA treatment showed no effect on phosphorylation
state of pRb. Combination of NVB plus MPA also induced the
accumulation of dephosphorylated pRb in the cells, as was the
case for NVB alone.
Recent results have shown that vinca alkaloid compounds, such
as vinblastine, can induce the expression of CDK inhibitor
p21wAF1/CIPI (Tishler et al, 1995). Under these circumstances, we
tested whether NVB, which is also a vinca alkaloid compound,
could induce the expression of p2lwAFI/CIPI in the cells using the
Western blotting method. As shown in Figure 6B, NVB did induce
the expression of p2lwA"1/ciPl protein in the cells (Figure 6B),
however MPA showed little, if any, effect on the expression level
of p2lWAF1/CIPT. Combination of NVB with MPA showed more
profound induction ofp21wAFI/cIP1 expression than such each drug
alone (Figure 6B).
We also examined the phosphorylation state of CDK2 protein,
which is one of the major Rb kinases in mammalian cells (Sherr
and Roberts, 1995). As shown in Figure 6C, NVB treatment
induced the decrease ofthe faster migrating protein band that was
previously shown to be an active and threonine 160-phosphoryl-
ated form of CDK2 protein (Schnier et al, 1994) in MCF-7 cells.
However, MPA treatmentexhibited noeffect on mobility ofCDK2
protein in the SDS gel. The combination of NVB with MPA
showed the same magnitude ofreduction on active CDK2 protein
as NVB alone (Figure 6C).
Combined effect of NVB with MPA on the expression of
cyclin proteins
Cyclin Dl, E and A proteins have been reported to be expressed
and to be degraded depending on cell-cycle phase in breast cancer
cells from G, to S-phase (Sutherland et al, 1995). Namely, cyclin
Dl protein is induced at early to midG,-phase, cyclin E protein is
induced at mid to late G,-phase and cyclin A protein induction
occurs at lateGI-phase to S-phase. To elucidate the arrest point of
MCF-7 cells treated with NVB and/orMPA in cell cyclephase, we
determined the expression levels of these cyclin proteins after
treatment with NVB and/or MPA using the Western blotting
method. As reported previously (Sutherland et al, 1995), MCF-7
cells were confirmed to express all the cyclin proteins tested and
the expression of cyclin Dl protein was most abundant (Figure
6D-F). Treatment ofthe cells with 2 nm ofNVB for 24 h showed
no effect on the expression level of both cyclin Dl and cyclin E
protein, while the expression level of cyclin A protein was
markedly reduced to a very low or undetectable level (Figure
6D-F). In contrast to these effects induced by NVB, MPA treat-
ment of the cells produced marked reduction ofcyclin Dl protein
level after 24 h, however the expression levels of cyclin A and
cyclin E protein were totally unchanged. Combination of NVB
plus MPA produced the reduced expression ofcyclin DI as well as
cyclin A protein, to the same extent as MPA or NVB alone without
any effect on cyclin E protein level (Figure 6D-F).
Isobologram analysis of the combined effect of NVB
with MPA for several breast cancer cell lines
The combination effect of NVB with MPA was further assessed
using isobologram analysis by simultaneous exposure to both
drugs for 144 h, using several human breast cancer cell lines, to
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Figure 5 Combined effect of NVB with MPA on cell cycle distribution of MCF-7 cells. (A) The cells were harvested after 24-, 48- and 72 h-treatment with NVB
(2 nM) alone, MPA (0.1 gM) alone, NVB plus MPA or without (control). The cells were harvested after 24-h treatment with 4 nm of NVB alone (B) and with 1 gM of
MPA alone (C). Cell fixation, RNA hydrolysis and DNA staining with propidium iodide were performed as described in Materials and methods. DNA histograms
were produced using flow cytometry
elucidate whether the combination effect was a general phenom-
enon in other human breast cancer cell lines. We used oestrogen
receptor (ER)- and progesterone receptor (PR)-positive cell lines,
such as T-47D, ZR-75-1 and BT-474 (Sutherland et al, 1988),
and ER- and PR-negative cell line MDA-MB-453 (Hall et al,
1994). As BT-474 and MDA-MB-453 cell lines failed to
respond to the growth-inhibitory effects of MPA alone, IC50 of
NVB was not affected by MPA. In T-47D and ZR-75-1 cell lines,
which are sensitive to MPA alone, the isobologram analysis ofthe
combination revealed that the combined effect was additive or
synergistic (Table 1).
DISCUSSION
Recent studies suggest that hormonal therapy combined with
chemotherapy termed chemohormonal therapy is expected to be
more beneficial than either of the therapies alone for advanced or
recurrent breast cancer (Tominaga et al, 1994). To understand the






























Figure 6 Combined effect of NVB with MPA on phosphorylation of Rb
protein and CDK2 protein, protein expression of CDK inhibitor p21WAF1/cIP1 and
cyclin proteins expression. MCF-7 cells were harvested after 24-h treatment
with NVB (2 nM) alone, MPA (0.1 gM) alone, NVB plus MPA or without
(control). Cell lysis and Western blotting were performed as described in
Materials and methods. Rb (A), p21 (B), CDK2 (C), cyclin Dl (D), cyclin E (E)
and cyclin A (F) proteins were each detected by specific antibodies
rationale for the combination modality of NVB, which has been
shown to be clinically effective against advanced breast carci-
noma, with MPA, one of the established therapies for tamoxifen-
resistant advanced breast carcinoma, we have assessed the
combined effect of both drugs using the cultured human breast
carcinoma cell line MCF-7 in vitro.
Results from classical isobologram analysis (Figure 2) as well as
median-effect plot analysis (Figure 3) revealed that the combined
effect ofNVB with MPA was synergistic over a wide range oftheir
concentrations against cultured human breast carcinoma MCF-7
cells. NVB has been shown to bind to tubulin, to prevent tubulin
polymerization and to induce M-phase block on cell cycle in target
cells (Fellous et al, 1989; Gomi et al, 1992). In contrast, MPA has
been shown to lead to G,-phase accumulation of MCF-7 cells
through unknown mechanism(s) (Sutherland et al, 1988). We
therefore suspected that regulation ofcell cycle progression might
play an important role on mechanism(s) ofaction ofthe combined
effect of NVB with MPA, and we have tested the effect of NVB
and/or MPA on cell cycle distribution ofMCF-7 cells. As reported
previously, MPA showed apparent GI-phase accumulation of
MCF-7 cells at0.1 and 1 ,UM (Figure 5A and C). Surprisingly, NVB
also induced G,-phase accumulation at 2 nM, which is a near 50%
growth-inhibitory concentration against MCF-7 cells, as shown in
Figure SA. The drug also induced G,-phase accumulation at 4 nm,
which is near a 90% growth-inhibitory concentration (Figure SB).
Combination of 2 nM NVB plus 0.1 JIM MPA also induced
apparent G,-phase accumulation in MCF-7 cells (Figure 5), which
was more profound than each drug alone, suggesting that the
synergistic combined effect of NVB and MPA might be mediated
through enhanced G,-phase accumulation.
Table 1 Combined effect of NVB with MPA in several human breast cancer
cell lines
Cell lines ERa PRb Combined effectsc
MCF-7 + + Synergistic
T-47D + + Additive
ZR-75-1 + + Synergistic
BT-474 + + No effect
MDA-MB-453 - - No effect
aER, oestrogen receptor. bPR, progesterone receptor. cCombined effect was
assessed by means of isobologram analysis using the IC50 values by
simultaneous exposure to both drugs for 144 h.
To gain some more insight into G,-phase accumulation induced
by each drug alone and the combination ofboth drugs, we assessed
the effect ofNVB and/orMPA on the expression andphosphoryla-
tion state ofcell cycle-regulatory proteins, such as Rb, p21WAFI/CIPI,
CDK2 and G, cyclins. NVB (2 nM) induced dephosphorylated
pRb and CDK2 protein as well as induction of CDK inhibitor
protein p21wAFl/cwPl in the cells, which was coincident with G,-
phase accumulation (Figure 6A-C). Treatment of cells with 4 nM
ofNVB also induced dephosphorylated pRb and the expression of
p21WAFI/CIPI protein (data not shown). In contrast to these effects of
NVB, 0.1JIM ofMPA had no effect on these cell cycle-regulatory
proteins (Figure 6A-C). Regarding the expression of G, cyclin
proteins, which constitutes a cell cycle marker in mammalian
cells, NVB showed the apparent reduction ofcyclin A, which is a
late G, to S and G2-phase marker, without any effect on cyclin Dl
and E (Figure 6D-F), suggesting that NVB accumulated the cells
in late G,-phase of the cell cycle. MPA induced a substantial
reduction in the expression ofcyclin Dl protein without any effect
on cyclin E and A (Figure 6D-F). Combination ofNVB plus MPA
induced an additive effect on dephosphorylation of pRb and
CDK2 protein and reduction of cyclin Dl and A, however the
induction of p21wA"IlCIPl might be synergistic (Figure 6). These
results suggest thatthe differential effect ofeach drug alone on cell
cycle-regulatory proteins might be important for the synergistic
combined effect.
Interestingly, recent reports have shown that mitotic poisons,
such as vinblastine (a vinca alkaloid compound) and taxol, could
induce the expression of p53 and p21WAF1/CIP1 in MCF-7 and
NIH3T3 cell lines (Blagosklonny et al, 1995; Tishler et al, 1995,
1996). Although these authors did not mention the effect of
vinblastine and/or taxol on cell-cycle distribution, it is quite
reasonable to suggest that these drugs exhibit G,-phase accumula-
tion through induction ofp21WAF1/CIP1. In addition, there is a report
showing that taxol could induce G,-phase accumulation in normal
ratfibroblast cells (Trielli et al, 1996). From these recentreports of
the effects ofmitotic poisons on the cell cycle, it might be reason-
able to expect that NVB would induce G,-phase accumulation in
cultured human cells, although its mechanism(s) ofaction remains
to be determined.
Regarding the mechanism(s) of action of G,-phase accumula-
tion induced by MPA, there is no explanation for this effect. As
cyclin Dl has been reported to regulate G, to S-phase progression
in mammalian cells (Jiang et al, 1993) and to also act as an onco-
gene (Motokura et al, 1991), our results suggest that reduction of
cyclin Dl protein might play an important role in G,-phase accu-
mulation induced by MPA (Figure 6). In addition, recent results
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showed that cyclin DI could activate oestrogen-responsive
elements in an oestrogen-independent manner in cultured breast
carcinoma cells (Zwijsen et al, 1997). More studies are needed on
the detailed mechanism(s) of action for MPA-induced G,-phase
accumulation.
We also studied the combined effect of NVB with MPA using
several human breast cancer cell lines to elucidate whether the
combined effect was a general phenomena in human breast cancer
cell lines. As BT-474 and MDA-MB-453 cell lines were insensi-
tive to MPA alone, we could not detect any combined effect. In T-
47D and ZR-75-1 cell lines, which were sensitive to MPA alone,
the isobologram analysis revealed that the combined effect was
additive or synergistic (Table 1), suggesting that the combination
ofNVB with MPA might be effective against human breast cancer
that is sensitive to MPA alone.
In conclusion, our studies suggest that the combination ofNVB
with MPA shouldbe considered as acandidate forclinical trials for
advanced breast cancer.
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